Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

NCT: NCT07333183 · RECRUITING

NCT IDNCT07333183
StatusRECRUITING
Start Date2025-12-23
Completion2028-01

Brief Summary

This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a background inhaled treprostinil.

Frequently Asked Questions

What is A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD?

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD is a clinical trial registered under NCT07333183. Current status: RECRUITING.

What is the status of NCT07333183?

The current status of NCT07333183 (A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD) is: RECRUITING.

When did A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD start?

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD started on 2025-12-23.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑